AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04669002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib tablets
Description: Olaparib is a PARP inhibitor (poly \[adenosine diphosphate-ribose\] polymerase inhibitor)
Study NCT00948415 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Evaluation of the Shape Up RI Campaign
Description: The SURI enhanced group will receive the standard Shape Up RI program. In addition, participants will be asked to record and report their daily calorie intake, body weight, minutes of physical activity, and pedometer steps. Participants will receive automated feedback on progress as well as a behavioral lesson delivered online during each week of the program. Participants assigned to the SURI Standard arm will receive the standard Shape Up RI program. The intervention will take place during the 12-week Shape Up RI campaign.
Study NCT00948415 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Evaluation of the Shape Up RI Campaign
Description: The SURI enhanced group will receive the standard Shape Up RI program. In addition, participants will be asked to record and report their daily calorie intake, body weight, minutes of physical activity, and pedometer steps. Participants will receive automated feedback on progress as well as a behavioral lesson delivered online during each week of the program. Participants assigned to the SURI Standard arm will receive the standard Shape Up RI program. The intervention will take place during the 12-week Shape Up RI campaign.
Study NCT02893111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib will be subcutaneously applicated in 4 treatment cycles with 4 injections of 1 mg Bortezomib /m2 body surface per cycle
Study NCT05633277 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Polidocanol
Description: Sclerotherapy of the ulcer bed (polidocanol, sodium tetradecyl, etc) either in conjunction with a greater saphenous vein ablation treatment (RFA, EVLT, Venaseal, Varithena) at the same time or 3 months later.
Study NCT05633277 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Polidocanol
Description: Sclerotherapy of the ulcer bed (polidocanol, sodium tetradecyl, etc) either in conjunction with a greater saphenous vein ablation treatment (RFA, EVLT, Venaseal, Varithena) at the same time or 3 months later.
Study NCT01665677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin calcium
Description: 40 mg PO daily
Study NCT04249518 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Videoeducation
Description: No drugs used. The only difference in the to arms is the way the extradition is.
Study NCT03025555 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PEEK
Description: Polyetheretherketone (PEEK) is a synthetic, tooth colored polymeric material that has been used as a biomaterial in orthopedics for many years but recently used as removable prosthetic material. Advantages of this polymer material are elimination of allergic reactions, high polishing qualities, low plaque affinity, and good wear resistance.~It has been proven that it shows high mechanical and biological properties. Studies evaluating the properties of this material are limited and need more clinical tests.
Study NCT03025555 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bre.flex
Description: Bre.flex is a nylon-based thermoplastic material, composed of nylon PA 12 (polyamide).Nylon exhibits high physical strength, heat resistance and chemical resistance. It can be easily modified to increase stiffness and wear resistance. Nylon resin can be semi-translucent and provides excellent esthetics but it is a little more difficult to adjust and polish.
Study NCT04678713 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: investigate the nutritional determinants of MFO in moderate to well-train individuals
Description: The participants will receive a 3-day fat rich or a carbohydrate rich diet. The participants will perform a maximal fat oxidation test before and after the diet intervention to evaluate the effect of the two diets on MFO.
Study NCT04678713 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Investigate the physiological determinants of MFO in moderate to well-train individuals
Description: Muscle biopsies will be obtained at baseline to compare muscle characteristics between well-matched train individuals with a high compared to a low maximal fat oxidation.
Study NCT03404050 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music and dance movement therapy
Description: Theoretically, the intervention adopts a humanistic approach of person centred care highlighting the importance of maintaining and enhancing personhood for older people with dementia.
Study NCT00039117 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: oblimersen sodium
Description: Given IV
Study NCT00039117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV
Study NCT00039117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin hydrochloride
Description: Given IV
Study NCT00039117 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00039117 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT03022578 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser Interstitial Thermal Therapy
Description: Undergo LITT
Study NCT03022578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lomustine
Description: Given PO
Study NCT03245762 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: 4 IU/day of oxytocin administered via nasal spray device each morning.
Study NCT03245762 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 IU/day of placebo administered via nasal spray device each morning
Study NCT03347266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VVZ-149 injections
Description: •VVZ-149 injection
Study NCT03347266 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: water for injection
Study NCT03765515 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Twinfix Ti
Description: The purpose is to evaluate the safety and efficacy of Q-Fix in patients requiring the repair of soft tissue of shoulder who receive the arthroscopic repair of soft tissue using Q-Fix, when compared with the patients receiving the treatment with Twinfix Ti Suture Anchor. The result of this trial will be used for the Q-Fix All-suture Anchor registration in China.
Study NCT03765515 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Q-Fix
Description: Q-Fix
Study NCT02762292 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Measurement of work of breathing using indirect calorimeter
Description: 1. Preparation:~   1. Patient baseline characteristics will be collected.~  2. Connection of the Indirect Calorimeter to the respiratory circuit.~  3. Nasogastric tube installation: a specific modified Neurally Adjusted Ventilatory Assist (NAVA) catheter equipped with both microelectrodes for Electrical Activity of the diaphragme (EAdi) monitoring and an esophageal balloon (for esophageal pressure (PES) monitoring) will be installed.~2. Simultaneous recordings of: Oxygen Consumption (VO2) and Energy Expenditure (EE); Esophageal Pressure (PES), Airway Pressure (PAW), respiratory volume and flow; EAdi during (i) Conventional mechanical ventilation (ii) Spontaneous Breathing Trial in Continuous Positive Airway Pressure and (iii) Second period of Conventional mechanical ventilation with the same ventilator parameters set in STEP 1.~3. End of the physiological recordings. Collection of Pediatric Intensive Care Unit (PICU) outcome of patients.
Study NCT02716688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: S-1 will be administered orally twice daily for 14 days at a dose of 70 mg/m2/day with concurrent radiotherapy for 2 cycles. Patients who showed a response greater than that of stable disease underwent additional S-1 until disease progression, serious adverse events, or patient refusal up to four cycles.
Study NCT02716688 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: Radiotherapy wiil be delivered with a daily fraction of 1.8 Gy to a total dose of 50.4 Gy.
Study NCT04016350 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training with Inulin Propionate Ester
Description: Supervised moderate intensity exercise training combined with Inulin Propionate Ester supplementation conducted for 4 weeks.
Study NCT04016350 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training with placebo
Description: Supervised moderate intensity exercise training combined with placebo conducted for 4 weeks
Study NCT02306083 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo three times a day
Study NCT02306083 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: glucosamine sulfate 1500 mg three times a day
Study NCT03294941 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: HepQuant SHUNT Liver Diagnostic Kit
Description: Serial testing over 48 weeks
Study NCT00787683 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Home-monitoring provided by LUMAX ICD device and CardioMessenger II
Description: All study participants receive an ICD of the Biotronik lumax family. Only participants of the intervention group receive the CardioMessengerII to allow for transmission of regular home monitoring messages. All study participants will be followed for 12 to 24 months (depending on the time of recruitment). The intervention and comparison to be investigated is home-monitoring vs. no home-monitoring. The intervention involves a combination of in-clinic consultations and regular use of home-monitoring services. As part of the modified follow-up schedule of intervention patients compared to standard care, follow-up in-clinic consultations 3, 6, and 18 months after ICD implantation will be replaced by home-monitoring follow-up.
Study NCT02943707 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow stem cells infusion
Description: Autologous bone marrow stem cells are infused into proper hepatic artery
Study NCT02943707 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: drugs such as Ursodeoxycholic Acid tablets
Description: Ursodeoxycholic Acid tablets(UDCA), each time 150 mg, three times a day orally
Study NCT02943707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: drugs such as Ursodeoxycholic Acid tablets
Description: Ursodeoxycholic Acid tablets(UDCA), each time 150 mg, three times a day orally
Study NCT00702650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone MD-Lotion
Description: 30 mg to 120 mg administered topically once daily for 120 days
Study NCT03408223 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: total body irradiation
Description: Drug: Cyclophosphamide 60 mg/kg/day intravenous x 2 days pre-transplant, total dose 120 mg/kg~Drug: Cyclosporine or tacrolimus Beginning on Day -1 pre-transplant maintaining a level of 150-250 ng/ml or 5-10 ng/ml respectively. Cyclosporine or tacrolimus dosing will be monitored and altered as clinically appropriate by physician, and discontinue at approximately day + 180 post-transplant.~Drug: Methotrexate 15 mg/m2 intravenous on days 1, 10 mg/m2 intravenous on days 3, 6 and 11 after transplantation.~Intervention: Total Body Irradiation Dose of 10 Gy TBI (fraction size of 5 Gy given once a day on days -2 and -1).~Procedure: Peripheral blood stem cell transplantation product will be infused via intravenous drip on Day 0.
Study NCT02564406 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LOW FLOW EXTRACORPOREAL CO2 REMOVAL, PROLUNG ESTOR
Study NCT02733575 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Compassion Focused Therapy
Description: Up to 26 sessions of Compassion Focused Therapy
Study NCT01853696 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: loteprednol etabonate
Study NCT01853696 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisolone acetate 1%
Study NCT04296786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: 200mg intravenously on day 1, every 21 days for 1 cycle, 96 weeks for protocol treatment
Study NCT04296786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide
Description: 20mg po per week continuously
Study NCT01084395 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adolescent Safer Sex Intervention
Description: Adolescents are randomly assigned to the HIV risk-reduction intervention condition. Adolescents receive a theory-based intervention designed to reduce HIV risk-associated behavior. The intervention consists of six 50-minute modules implemented over the course of two days. The intervention is highly interactive and includes games, videos, discussion, and role-plays.
Study NCT01084395 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Safer Sex Communication Intervention
Description: Parents are randomly assigned to the Safer Sex Communication Intervention. Parents learn about HIV and other consequences of unprotected sexual behavior. The intervention contains content that focuses on enhancing parent-adolescent communication.
Study NCT01084395 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Adolescent Health Promotion Control Condition
Description: Adolescents are randomly assigned to the Health Promotion control condition. Adolescents receive an intervention aimed at significant health problems affecting Mexicans that are related, not to sexual behavior, but to other behaviors. These health problems include heart disease, certain cancers, and diabetes. Adolescents are taught that these health problems can be prevented by changing personal behaviors, primarily exercise, diet, cigarette smoking, and alcohol and drug use.
Study NCT01084395 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Parent Health Promotion Control Condition
Description: Parents are randomly assigned to the Health Promotion control condition. Parents receive an intervention aimed at significant health problems affecting Mexicans that are related, not to sexual behavior, but to other behaviors. These health problems include heart disease, certain cancers, and diabetes. Parents will be taught that these health problems can be prevented by changing personal behaviors, primarily exercise, diet, cigarette smoking, and alcohol and drug use. The intervention also provides content that emphasizes the importance of families.
Study NCT00986947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVIg and rituximab
Description: A maximum of four doses (each single dose being 2gm/kg) of IVIg will be administered over a four-month period, with one dose administered each month. Each single dose of 2gm/kg will be administered in two half-doses (1gm/kg each) to be given one day apart, with one day of hemodialysis on the intervening day between the two half-doses.~If a compatible kidney transplant organ offer is received, upon admission to the hospital and immediately prior to the transplant operation, patients will receive a single infusion of Rituximab (375 mg/m2 BSA).
Study NCT02101749 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: trivalent inactivated influenza
Description: intradermal or intramuscular injection in the deltoid area.
Study NCT03112733 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: TFF3, SFRP4, Romo1, NFKB
Description: Blood samples of all participants will be collected.
Study NCT03398239 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Noninvasive mechanical ventilation
Study NCT03398239 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Noninvasive mechanical ventilation
Study NCT03387345 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 100% steel cut barley
Description: 25 g of available carbohydrate was delivered to participants via steel cut Sustagrain barley (Ardent Mills, LLC).
Study NCT03387345 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 100% barley flakes
Description: 25 g of available carbohydrate was delivered to participants via Sustagrain barley flakes (Ardent Mills, LLC).
Study NCT03387345 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 50/50 rice-barley mix
Description: 25 g of available carbohydrate was delivered to participants via a 50/50 mixture (by weight) of Goya medium grain white rice and steel cut Sustagrain barley (Ardent Mills, LLC).
Study NCT03387345 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 80/20 rice-barley mix
Description: 25 g of available carbohydrate was delivered to participants via a 80/20 mixture (by weight) of Goya medium grain white rice and steel cut Sustagrain barley (Ardent Mills, LLC).
Study NCT03387345 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 100% rice
Description: 25 g of available carbohydrate was delivered to participants via Goya medium grain white rice
Study NCT03387345 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: white bread
Description: 25 g of available carbohydrate was delivered to participants via Sara Lee Classic White Bread (Bimbo Bakeries USA, Inc.)
Study NCT04459598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz
Description: Single oral dose, 600-mg tablet
Study NCT04459598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quizartinib
Description: Single oral dose, 60 mg (2 x 30 mg) tablets
Study NCT04459598 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quizartinib
Description: Single oral dose, 60 mg (2 x 30 mg) tablets
Study NCT03105921 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NanoKnife
Description: The aim of the treatment is to sourround the tumour with two to six needles and to deliver a very high voltage current (3000 volts in 70 to 80 microseconds pulses) by a generator synchronized with an electrocardiogram.
Study NCT02685072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone (200 mgs BID)
Description: Transdermal Nicotine Patch (TNP) + Progesterone
Study NCT02685072 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: TNP + Placebo
Study NCT02503254 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CHTP 1.0
Description: CHTP 1.0 ad libitum for 5 days in confinement
Study NCT02503254 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Cigarette (CC)
Description: Subject's own preferred brand of CC ad libitum for 5 days in confinement
Study NCT02144636 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: herbalife protein shake
Study NCT02608008 — intervention group
Intervention type: DEVICE
Intervention: Data analysis
Description: data parameters Analysis
Study NCT03623295 — intervention group
Intervention type: OTHER
Intervention: Blood sample
Description: Blood withdrawal.
Study NCT03623295 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: Online questionnaire about the bleeds that patients experienced in the past.
Study NCT03623295 — intervention group
Intervention type: OTHER
Intervention: MRI-imaging
Description: MRI imaging of joints.
Study NCT03623295 — intervention group
Intervention type: OTHER
Intervention: Physical examination
Description: Physical examination of joint status.
Study NCT04268628 — intervention group
Intervention type: OTHER
Intervention: Serum and plasma samples analysis
Description: This is a non-interventional study and no drug will be given as part of this study. Serum and plasma samples will be collected from the participants with metastatic castration-resistant prostate cancer to evaluate genetic polymorphism and pharmacodynamic parameters.
Study NCT05611996 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Peers plus
Description: Peer support intervention in which peer mentors who have experiential knowledge of depression deliver social support through video chats and texting to older adults with depression.
Study NCT02634905 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individual session therapeutic education
Description: within 2 weeks after inclusion (week 0)
Study NCT02634905 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phone Call
Study NCT03528057 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hemostat
Description: Hemostatic agents, if used at all during surgery, will be applied laparoscopically into the tumor bed to stop bleeding. The type of hemostat will be decided by the surgeon according to the anatomy of the tumor bed.
Study NCT00772005 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: armodafinil
Description: 150 mg/day armodafinil
Study NCT00772005 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT00772005 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: armodafinil
Description: 200 mg/day armodafinil
Study NCT03752619 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contracting Producing Peripheral Nerve Stimulation
Description: The stimulation system includes an external stimulator, percutaneous lead and pad. The stimulator snaps onto the pad. The pad has an embedded power source but also serves as the anode. The 1-channel stimulator outputs a biphasic current waveform with current pulse parameter ranges suitable for Peripheral Nerve Stimulation (PNS). The percutaneous lead is inserted using an introducer (like a hypodermic needle) which is withdrawn and the lead is retained in the muscle by a barb at its tip. After a 1-week stabilization period, stimulation is initiated (6 hrs/day). The duty cycle and daily dose remain constant, but stimulus parameters may be adjusted by the research staff as deemed appropriate. The treatment period is 3 weeks after which the lead will be removed.